Kenneth Kovan
Founder at BIOVAXYS TECHNOLOGY CORP.
Net worth: 411 760 $ as of 2024-03-30
Kenneth Kovan active positions
| Companies | Position | Start | End |
|---|---|---|---|
| BIOVAXYS TECHNOLOGY CORP. | Chief Operating Officer | - | - |
| Founder | - | - | |
| President | - | - | |
Chaperone Technologies, Inc.
 Chaperone Technologies, Inc. Medical SpecialtiesHealth Technology Chaperone Technologies, Inc. develops novel products for infectious diseases. The firm develops and produces peptide-based antimicrobial products to treat infectious diseases. The company was founded by Michael and Elisabeth Lang in March 2014 and is headquartered in Bogart, GA. | President | - | - |
| Chief Executive Officer | - | 2011-12-31 | |
BioVaxys LLC
 BioVaxys LLC BiotechnologyHealth Technology BioVaxys LLC is a clinical stage biotechnology company, which engages in the development of immunotherapeutic vaccines for antiviral and individualized cancer therapy. It focuses on multihaptenized autologous vaccine that will initially be developed and marketed for melanoma and ovarian cancer. The company was founded by James Passin, Kenneth Kovan and David Berd and is headquartered in New York, NY. | Chief Operating Officer | - | - |
| Founder | - | - | |
| President | - | - | |
| Bingham Hill Ventures | Corporate Officer/Principal | - | - |
Career history of Kenneth Kovan
Former positions of Kenneth Kovan
| Companies | Position | Start | End |
|---|---|---|---|
Horizon Discovery Ltd.
 Horizon Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - | - |
| Wyeth-Ayerst Research | Corporate Officer/Principal | - | - |
| GSK PLC | Corporate Officer/Principal | - | - |
| Thomas Jefferson University | Corporate Officer/Principal | - | - |
| AVAX TECHNOLOGIES, INC. | Founder | 2010-01-05 | - |
| Corporate Officer/Principal | 1990-01-11 | 2010-01-05 |
Statistics
International
| United States | 7 |
| United Kingdom | 3 |
| Canada | 2 |
Operational
| Corporate Officer/Principal | 6 |
| Founder | 3 |
| President | 3 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
| Non-Energy Minerals | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| AVAX TECHNOLOGIES, INC. | Health Technology |
| GSK PLC | Health Technology |
| BIOVAXYS TECHNOLOGY CORP. | Non-Energy Minerals |
| Private companies | 5 |
|---|---|
| Wyeth-Ayerst Research | |
Chaperone Technologies, Inc.
Chaperone Technologies, Inc. Medical SpecialtiesHealth Technology Chaperone Technologies, Inc. develops novel products for infectious diseases. The firm develops and produces peptide-based antimicrobial products to treat infectious diseases. The company was founded by Michael and Elisabeth Lang in March 2014 and is headquartered in Bogart, GA. | Health Technology |
BioVaxys LLC
BioVaxys LLC BiotechnologyHealth Technology BioVaxys LLC is a clinical stage biotechnology company, which engages in the development of immunotherapeutic vaccines for antiviral and individualized cancer therapy. It focuses on multihaptenized autologous vaccine that will initially be developed and marketed for melanoma and ovarian cancer. The company was founded by James Passin, Kenneth Kovan and David Berd and is headquartered in New York, NY. | Health Technology |
| Bingham Hill Ventures | |
Horizon Discovery Ltd.
Horizon Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
- Stock Market
- Insiders
- Kenneth Kovan
- Experience
